Diabetes and Depression Just Got Linked in a New Way
A 2026 meta-analysis published in Frontiers in Medicine and supported by a NYU nursing report and a 2026 PubMed-listed review found that Type 2 diabetes and depression share a stronger bidirectional relationship than previously understood — adults with depression have a 60% higher risk of developing Type 2 diabetes, and adults with Type 2 diabetes […]
Beta Cells May Need Rhythmic Rest to Function.
New lab research published this month suggests that rhythmic “rest breaks” in pancreatic beta cells help preserve insulin-producing function in Type 2 diabetes, rather than continuously stimulating them. The study, reported by Ohio University researchers and detailed in Science Daily coverage, showed better glucose sensing, improved calcium signaling, and lower cellular stress when beta cells […]
DiRECT Just Showed 5-Year Remission Is Real. It’s Still Not a Cure.
The DiRECT trial — the landmark structured weight-management trial in Type 2 diabetes — just published its 5-year follow-up, showing that remission is possible and durable when weight loss is maintained. At 1 year, 46% of participants in the intervention group were in remission, per the DiRECT primary trial report in The Lancet. At 2 […]
Novo’s Next GLP-1 Just Hit 89% A1c Target
Novo Nordisk’s next-generation triple-agonist zenagamtide just hit 89.1% A1c target attainment in phase 2 — one of the highest rates ever reported for a Type 2 diabetes therapy, per the ADA 2026 Scientific Sessions coverage and the Novo Nordisk pipeline announcement. In adults with Type 2 diabetes, the highest dose produced 14.6% body-weight loss and […]
Strength Training Plus Cardio Just Cut Diabetes Risk
A new meta-analysis published in Sports Medicine and reported by News-Medical.net found that combining strength training with aerobic exercise cuts Type 2 diabetes risk more than either modality alone. Across 35 studies and over 90,000 participants, the combination reduced Type 2 diabetes risk by 17–40% depending on dose, with the strongest effect at 150+ minutes […]
An Oral GLP-1 Just Hit 89% A1c Target
A new phase 2b trial of Eli Lilly’s investigational oral GLP-1 elecoglipron showed that up to 89.6% of participants with Type 2 diabetes reached an A1c of 7% or lower, compared with just 24.9% on placebo —and up to 72.3% achieved at least 5% weight loss versus 20.2% on placebo. The results, presented this week […]
Retatrutide Just Got Renal Data
Eli Lilly’s retatrutide — the triple-hormone receptor agonist that already made headlines in 2026 for its 2.0% A1c reduction and 16.8% body-weight loss in Type 2 diabetes — just published renal outcomes data in The New England Journal of Medicine. The ORBIT trial evaluated retatrutide in adults with Type 2 diabetes and chronic kidney disease, […]
Stanford Just Found Why GLP-1s Don’t Work for 1 in 10 People
Stanford researchers just published findings that roughly 1 in 10 people carry genetic variants that make GLP-1 receptor agonist drugs — Ozempic, Mounjaro, Wegovy — meaningfully less effective at lowering blood sugar. The Stanford Medicine News report describes a meta-analysis of three clinical trials showing that carriers of specific variants in the PAM gene reach […]
Generic Dapagliflozin Just Got Approved.
The FDA has approved generic versions of dapagliflozin, a workhorse Type 2 diabetes medication in the SGLT2 inhibitor class, and the coverage has been almost entirely about access. Lower cost. More refills. Fewer prior-authorization fights at the pharmacy counter. For the millions of adults in the US who take a daily SGLT2 inhibitor to lower […]
ADA 2026 Made Multimorbidity the Headline.
At the 2026 ADA Scientific Sessions in New Orleans, a team from Leicester launched a three-paper Lancet Series on cardiometabolic multimorbidity — and the agenda tells you exactly where the diabetes conversation is right now. What the Lancet Series Covers The Leicester/NIHR ARC East Midlands team presented three new papers in The Lancet on June […]